Parkinson Disease Cognition Improved in Phase 2 Study of TAK-071

A recent clinical trial tested a new medication called TAK-071 for improving thinking and memory in people with Parkinson's disease (PD). The trial involved 54 patients aged 40 to 85, and results showed that those taking TAK-071 experienced better cognitive function compared to those on a placebo (inactive pill). However, the medication did not improve their walking abilities. During the 6-week study, participants on TAK-071 had a noticeable improvement in their global cognitive scores. Researchers aimed to see if TAK-071 could also help with gait, but the results showed no significant change in walking patterns for those on the medication compared to the placebo group. The study was presented at an important Parkinson’s disease conference in Philadelphia. It was led by Dr. Niraj Shanbhag from Takeda. Patients were already on stable Parkinson's treatments and were monitored for any side effects. While some experienced mild gastrointestinal issues, no severe side effects were reported. The M1 receptor, which plays a role in cognitive function, was the target for TAK-071. Earlier studies have shown promise for this receptor in treating cognitive problems associated with both Alzheimer's and Parkinson's diseases. Overall, the trial suggests that TAK-071 may be a safe and effective option for improving cognition in people with Parkinson's, but more research is needed to understand its full effects.